Abstract：
OBJECTIVE: This study aimed to compare the pharyngocutaneous fistula (PCF) between patients who underwent reconstruction using cervical fascia after total laryngectomy and those who did not and to investigate the factors affecting PCF rates.
METHODS: We retrospectively compared 22 patients operated between February 2021 and March 2023 who received cervical fascia flap as the study group and 21 patients operated between January 2018 and March 2023 who did not receive fascia flap as the control group. The study included patients who underwent total laryngectomy for Stage 3 and 4 squamous cell laryngeal cancer.
RESULTS: We included 43 patients, with 22 (51.2%) and 21 patients (48.8%) in the study and control groups, respectively. The age and sex were not different between the two groups (p = 0.471, p = 0.176, respectively). The distribution of patients as per sex, smoking, alcohol use, chronic obstructive pulmonary disease, diabetes mellitus, coronary artery disease, and multiple comorbidities was similar in both groups (p > 0.05). PCF was observed in one patient (4.5%) and seven patients (33.3%) in the study and control groups, respectively. The PCF rate was significantly lower in the study group (p = 0.021). When the relationship between flap use and risk factors was compared by correlation analysis, a moderate negative relationship was found between flap use and PCF (p = 0.015, r = -0.370).
CONCLUSIONS: The use of a cervical fascia flap is effective in reducing fistula rates after total laryngectomy. Its main advantages include being technically simpler than alternative techniques, locally available, cost-effective.
METHODS: Level 3 Laryngoscope, 2024.
METHODS: We retrospectively compared 22 patients operated between February 2021 and March 2023 who received cervical fascia flap as the study group and 21 patients operated between January 2018 and March 2023 who did not receive fascia flap as the control group. The study included patients who underwent total laryngectomy for Stage 3 and 4 squamous cell laryngeal cancer.
RESULTS: We included 43 patients, with 22 (51.2%) and 21 patients (48.8%) in the study and control groups, respectively. The age and sex were not different between the two groups (p = 0.471, p = 0.176, respectively). The distribution of patients as per sex, smoking, alcohol use, chronic obstructive pulmonary disease, diabetes mellitus, coronary artery disease, and multiple comorbidities was similar in both groups (p > 0.05). PCF was observed in one patient (4.5%) and seven patients (33.3%) in the study and control groups, respectively. The PCF rate was significantly lower in the study group (p = 0.021). When the relationship between flap use and risk factors was compared by correlation analysis, a moderate negative relationship was found between flap use and PCF (p = 0.015, r = -0.370).
CONCLUSIONS: The use of a cervical fascia flap is effective in reducing fistula rates after total laryngectomy. Its main advantages include being technically simpler than alternative techniques, locally available, cost-effective.
METHODS: Level 3 Laryngoscope, 2024.
摘要：
目的：本研究旨在比较全喉切除术后使用颈筋膜重建的患者与未使用颈筋膜重建的患者之间的咽皮瘘（PCF），并探讨影响PCF发生率的因素。
方法：我们回顾性比较了在2021年2月至2023年3月期间接受颈筋膜皮瓣手术的22例患者作为研究组，在2018年1月至2023年3月期间未接受筋膜皮瓣手术的21例患者作为对照组。该研究包括接受全喉切除术治疗3期和4期鳞状细胞喉癌的患者。
结果：我们纳入了43例患者，研究组和对照组分别为22例（51.2%）和21例（48.8%），分别。两组之间的年龄和性别没有差异（分别为p=0.471，p=0.176）。患者按性别分布，吸烟,酒精使用,慢性阻塞性肺疾病,糖尿病,冠状动脉疾病,两组的多种合并症相似(p>0.05)。在研究组和对照组中，有1例患者（4.5％）和7例患者（33.3％）观察到PCF，分别。研究组PCF发生率明显较低(p=0.021)。通过相关性分析比较皮瓣使用与危险因素之间的关系，发现皮瓣使用与PCF之间存在中度负相关（p=0.015，r=-0.370）。
结论：使用颈筋膜瓣可有效降低全喉切除术后的瘘发生率。它的主要优点包括在技术上比替代技术更简单，本地可用,成本效益。
方法：三级喉镜，2024.
方法：我们回顾性比较了在2021年2月至2023年3月期间接受颈筋膜皮瓣手术的22例患者作为研究组，在2018年1月至2023年3月期间未接受筋膜皮瓣手术的21例患者作为对照组。该研究包括接受全喉切除术治疗3期和4期鳞状细胞喉癌的患者。
结果：我们纳入了43例患者，研究组和对照组分别为22例（51.2%）和21例（48.8%），分别。两组之间的年龄和性别没有差异（分别为p=0.471，p=0.176）。患者按性别分布，吸烟,酒精使用,慢性阻塞性肺疾病,糖尿病,冠状动脉疾病,两组的多种合并症相似(p>0.05)。在研究组和对照组中，有1例患者（4.5％）和7例患者（33.3％）观察到PCF，分别。研究组PCF发生率明显较低(p=0.021)。通过相关性分析比较皮瓣使用与危险因素之间的关系，发现皮瓣使用与PCF之间存在中度负相关（p=0.015，r=-0.370）。
结论：使用颈筋膜瓣可有效降低全喉切除术后的瘘发生率。它的主要优点包括在技术上比替代技术更简单，本地可用,成本效益。
方法：三级喉镜，2024.
